vs
Side-by-side financial comparison of Digital Realty (DLR) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Digital Realty is the larger business by last-quarter revenue ($1.6B vs $1.1B, roughly 1.5× PERRIGO Co plc). Digital Realty runs the higher net margin — 6.0% vs -127.8%, a 133.8% gap on every dollar of revenue. On growth, Digital Realty posted the faster year-over-year revenue change (16.1% vs -2.5%). Over the past eight quarters, Digital Realty's revenue compounded faster (9.8% CAGR vs 1.3%).
Digital Realty is a real estate investment trust that owns, operates and invests in carrier-neutral data centers across the world. The company offers data center, colocation, and interconnection services.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
DLR vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $1.1B |
| Net Profit | $98.6M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 6.9% | -116.0% |
| Net Margin | 6.0% | -127.8% |
| Revenue YoY | 16.1% | -2.5% |
| Net Profit YoY | -10.3% | -3093.9% |
| EPS (diluted) | $0.22 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.4B | $1.1B | ||
| Q3 24 | $1.4B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B |
| Q1 26 | $98.6M | — | ||
| Q4 25 | $98.6M | $-1.4B | ||
| Q3 25 | $67.8M | $7.5M | ||
| Q2 25 | $1.0B | $-8.4M | ||
| Q1 25 | $110.0M | $-6.4M | ||
| Q4 24 | $189.6M | $-44.4M | ||
| Q3 24 | $51.2M | $-21.0M | ||
| Q2 24 | $80.2M | $-108.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% |
| Q1 26 | 6.9% | — | ||
| Q4 25 | 6.9% | -116.0% | ||
| Q3 25 | 8.8% | 7.0% | ||
| Q2 25 | 14.2% | 4.3% | ||
| Q1 25 | 13.9% | 4.5% | ||
| Q4 24 | 10.1% | 10.0% | ||
| Q3 24 | 11.8% | 7.4% | ||
| Q2 24 | 0.7% | -2.5% |
| Q1 26 | 6.0% | — | ||
| Q4 25 | 6.0% | -127.8% | ||
| Q3 25 | 4.3% | 0.7% | ||
| Q2 25 | 69.1% | -0.8% | ||
| Q1 25 | 7.8% | -0.6% | ||
| Q4 24 | 13.2% | -3.9% | ||
| Q3 24 | 3.6% | -1.9% | ||
| Q2 24 | 5.9% | -10.2% |
| Q1 26 | $0.22 | — | ||
| Q4 25 | $0.22 | $-10.23 | ||
| Q3 25 | $0.15 | $0.05 | ||
| Q2 25 | $2.94 | $-0.06 | ||
| Q1 25 | $0.27 | $-0.05 | ||
| Q4 24 | $0.50 | $-0.32 | ||
| Q3 24 | $0.09 | $-0.15 | ||
| Q2 24 | $0.20 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.9B | $2.9B |
| Total Assets | $49.4B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.3B | $432.1M | ||
| Q2 25 | $3.6B | $454.2M | ||
| Q1 25 | $2.3B | $409.9M | ||
| Q4 24 | $3.9B | $558.8M | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.3B | $542.8M |
| Q1 26 | $22.9B | — | ||
| Q4 25 | $22.9B | $2.9B | ||
| Q3 25 | $23.0B | $4.4B | ||
| Q2 25 | $22.9B | $4.5B | ||
| Q1 25 | $21.3B | $4.4B | ||
| Q4 24 | $21.3B | $4.3B | ||
| Q3 24 | $21.2B | $4.6B | ||
| Q2 24 | $20.5B | $4.5B |
| Q1 26 | $49.4B | — | ||
| Q4 25 | $49.4B | $8.5B | ||
| Q3 25 | $48.7B | $10.1B | ||
| Q2 25 | $48.7B | $10.1B | ||
| Q1 25 | $45.1B | $9.8B | ||
| Q4 24 | $45.3B | $9.6B | ||
| Q3 24 | $45.3B | $11.2B | ||
| Q2 24 | $43.6B | $10.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $719.0M | $175.4M | ||
| Q3 25 | $652.9M | $51.7M | ||
| Q2 25 | $641.2M | $75.9M | ||
| Q1 25 | $399.1M | $-64.5M | ||
| Q4 24 | $769.5M | $312.6M | ||
| Q3 24 | $566.5M | $42.2M | ||
| Q2 24 | $573.2M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $148.6M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 7.29× | — | ||
| Q3 25 | 9.63× | 6.89× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 3.63× | — | ||
| Q4 24 | 4.06× | — | ||
| Q3 24 | 11.07× | — | ||
| Q2 24 | 7.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLR
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
